This case study explains the global differences in test reimbursement and reveals that for some tests the laboratories own costs aren't even covered....
Peter Keeling of Diaceutics comments on Google’s announcement that it will create Calico, a new type of company focused on disease management, and highlights how it is a game changer in the personalized medicine space.
At an offsite meeting of Diaceutics management team some two years ago, we defined a small number of events which would signal a tectonic shift towards a predominantly personalized model for the pharmaceutical and diagnostic industries. Since that time two of the events have already occurred: the $1000 genome and the realization of accelerated FDA approvals for biomarker-targeted therapies. A third was revealed over the past few days  and it’s called Calico. See news here – http://www.latimes.com/business/la-fi-google-aging-20130919,0,6335069.story.
Calico is Google’s second venture into health care (remember their first, the failed Google Health EHR initiative?) and this time it is to build a new type of company focused on disease management. Details are scant about how Calico will go about its business, but we should not be waylaid by the absence of details at this stage since what is more important is to focus on the four huge competitive advantages Google collectively have over most other pharmaceutical incumbents:
For these reasons, Calico is a personalized medicine game changer.